Exelixis, Inc. (EXEL) CMO Sells $169,920.00 in Stock

Exelixis, Inc. (NASDAQ:EXEL) CMO Gisela Schwab sold 12,000 shares of the stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $14.16, for a total value of $169,920.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Gisela Schwab also recently made the following trade(s):

  • On Monday, October 1st, Gisela Schwab sold 12,000 shares of Exelixis stock. The shares were sold at an average price of $17.77, for a total value of $213,240.00.
  • On Tuesday, September 4th, Gisela Schwab sold 22,500 shares of Exelixis stock. The shares were sold at an average price of $18.53, for a total value of $416,925.00.

Shares of NASDAQ EXEL opened at $17.41 on Monday. Exelixis, Inc. has a 52-week low of $13.42 and a 52-week high of $32.20. The company has a market cap of $5.21 billion, a price-to-earnings ratio of 14.75 and a beta of 2.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.54 and a current ratio of 8.66.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Thursday, November 1st. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.19 by $0.22. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. The firm had revenue of $225.40 million for the quarter, compared to analysts’ expectations of $174.14 million. During the same quarter in the prior year, the firm posted $0.26 earnings per share. Exelixis’s revenue for the quarter was up 47.8% compared to the same quarter last year. As a group, equities research analysts predict that Exelixis, Inc. will post 1.03 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. James Investment Research Inc. acquired a new stake in Exelixis during the second quarter valued at approximately $133,000. Polaris Greystone Financial Group LLC acquired a new stake in Exelixis during the third quarter valued at approximately $177,000. Fox Run Management L.L.C. acquired a new stake in Exelixis during the third quarter valued at approximately $183,000. Advisors Asset Management Inc. raised its stake in Exelixis by 94.7% during the second quarter. Advisors Asset Management Inc. now owns 41,168 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 20,025 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. acquired a new stake in Exelixis during the second quarter valued at approximately $217,000. Hedge funds and other institutional investors own 81.84% of the company’s stock.

A number of research analysts recently commented on the company. BidaskClub downgraded Exelixis from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 24th. Oppenheimer set a $40.00 price target on Exelixis and gave the company a “buy” rating in a report on Thursday. Zacks Investment Research raised Exelixis from a “hold” rating to a “strong-buy” rating and set a $25.00 price target for the company in a report on Tuesday, July 31st. Stifel Nicolaus reduced their price target on Exelixis from $29.00 to $25.00 and set a “hold” rating for the company in a report on Wednesday, August 1st. Finally, Morgan Stanley assumed coverage on Exelixis in a report on Monday, September 10th. They issued an “underweight” rating and a $19.00 price target for the company. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $29.78.

About Exelixis

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Read More: What are earnings reports?

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply